WallStSmart

CryoCell International Inc (CCEL)vsEli Lilly and Company (LLY)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 277675% more annual revenue ($86.46B vs $31.13M). LLY leads profitability with a 31.9% profit margin vs -6.3%. LLY appears more attractively valued with a PEG of 1.33. LLY earns a higher WallStSmart Score of 74/100 (B).

CCEL

Hold

47

out of 100

Grade: D+

Growth: 6.0Profit: 5.0Value: 7.0Quality: 5.5
Piotroski: 6/9Altman Z: -0.53

LLY

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCELUndervalued (+33.5%)

Margin of Safety

+33.5%

Fair Value

$5.02

Current Price

$4.15

$0.87 discount

UndervaluedFair: $5.02Overvalued

Intrinsic value data unavailable for LLY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEL3 strengths · Avg: 10.0/10
Return on EquityProfitability
129.2%10/10

Every $100 of equity generates 129 in profit

EPS GrowthGrowth
75.1%10/10

Earnings expanding 75.1% YoY

Debt/EquityHealth
-0.0410/10

Conservative balance sheet, low leverage

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$1.27T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
68.5%10/10

Every $100 of equity generates 68 in profit

Profit MarginProfitability
31.9%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
51.2%10/10

Strong operational efficiency at 51.2%

Revenue GrowthGrowth
38.6%10/10

Revenue surging 38.6% year-over-year

Free Cash FlowQuality
$8.22B8/10

Generating 8.2B in free cash flow

Areas to Watch

CCEL4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$39.10M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.6%3/10

Operating margin of 0.6%

Altman Z-ScoreHealth
-0.532/10

Distress zone — elevated risk

LLY3 concerns · Avg: 2.3/10
Debt/EquityHealth
1.233/10

Elevated debt levels

P/E RatioValuation
46.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
29.8x2/10

Trading at 29.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEL

The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.

Bear Case : CCEL

The primary concerns for CCEL are Revenue Growth, Market Cap, Operating Margin.

Bear Case : LLY

The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.

Key Dynamics to Monitor

CCEL profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.

CCEL carries more volatility with a beta of 0.55 — expect wider price swings.

LLY is growing revenue faster at 38.6% — sustainability is the question.

LLY generates stronger free cash flow (8.2B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (74/100 vs 47/100), backed by strong 31.9% margins and 38.6% revenue growth. CCEL offers better value entry with a 33.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CryoCell International Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?